HASBROUCK HEIGHTS, N.J., Feb. 9, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The first Safety Monitoring Committee meeting of 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated an acceptable ongoing safety evaluation of the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 60 well-known urology investigative sites throughout the U.S. The participating centers continue to evaluate and enroll patients and accrual is progressing well. The current Phase 3 trials incorporate specific protocol design recommendations made by the FDA at the earlier EOP2 meeting with the Company. For more information about the NX-1207 Phase 3 clinical trials, please go to www.clinicaltrials.gov or contact Nymox at info@nymox.com.
